CY1125751T1 - Συμπλοκα πρωτεϊνων-πολυμερων - Google Patents

Συμπλοκα πρωτεϊνων-πολυμερων

Info

Publication number
CY1125751T1
CY1125751T1 CY20221100538T CY221100538T CY1125751T1 CY 1125751 T1 CY1125751 T1 CY 1125751T1 CY 20221100538 T CY20221100538 T CY 20221100538T CY 221100538 T CY221100538 T CY 221100538T CY 1125751 T1 CY1125751 T1 CY 1125751T1
Authority
CY
Cyprus
Prior art keywords
protein
polymers complexes
complexes
polymers
hepatitis
Prior art date
Application number
CY20221100538T
Other languages
English (en)
Inventor
Ko-Chung Lin
Original Assignee
Pharmaessentia Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351178&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1125751(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmaessentia Corp. filed Critical Pharmaessentia Corp.
Publication of CY1125751T1 publication Critical patent/CY1125751T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στα σύμπλοκα πρωτεϊνών- πολυμερών που περιγράφονται στη περιγραφή. Επίσης περιγράφεται μια μέθοδος για τη παρασκευή ενός συμπλόκου πρωτεΐνης-πολυμερούς και η χρήση του στη θεραπεία της λοίμωξης από ιό ηπατίτιδας Β ή ιό ηπατίτιδας C.
CY20221100538T 2007-08-16 2022-08-05 Συμπλοκα πρωτεϊνων-πολυμερων CY1125751T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95627307P 2007-08-16 2007-08-16
PCT/US2008/073290 WO2009023826A1 (en) 2007-08-16 2008-08-15 Protein-polymer conjugates

Publications (1)

Publication Number Publication Date
CY1125751T1 true CY1125751T1 (el) 2023-06-09

Family

ID=40351178

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100538T CY1125751T1 (el) 2007-08-16 2022-08-05 Συμπλοκα πρωτεϊνων-πολυμερων

Country Status (30)

Country Link
US (1) US8143214B2 (el)
EP (2) EP4129343A1 (el)
JP (1) JP5613050B2 (el)
KR (1) KR101588465B1 (el)
CN (1) CN101367872B (el)
AR (1) AR067964A1 (el)
AU (1) AU2008286742B2 (el)
BR (1) BRPI0814482B8 (el)
CA (1) CA2696478C (el)
CL (1) CL2008002399A1 (el)
CY (1) CY1125751T1 (el)
DK (1) DK2205281T3 (el)
EA (1) EA018111B1 (el)
ES (1) ES2924727T3 (el)
FR (1) FR22C1045I2 (el)
HR (1) HRP20220937T3 (el)
HU (2) HUE059551T2 (el)
LT (1) LT2205281T (el)
MX (1) MX2010001750A (el)
MY (1) MY149148A (el)
NL (1) NL301195I2 (el)
NO (1) NO2022038I1 (el)
NZ (1) NZ583831A (el)
PL (1) PL2205281T3 (el)
PT (1) PT2205281T (el)
SI (1) SI2205281T1 (el)
TW (1) TWI381851B (el)
UA (1) UA103158C2 (el)
WO (1) WO2009023826A1 (el)
ZA (1) ZA201001777B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020347B1 (ru) * 2008-07-31 2014-10-30 Фармаиссэншиа Корп. Пептид-полимерные конъюгаты
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
MY191506A (en) * 2014-11-06 2022-06-28 Pharmaessentia Corp Dosage regimen for pegylated interferon
CN112433048A (zh) * 2020-11-17 2021-03-02 深圳上泰生物工程有限公司 一种用于化学发光免疫法的试剂盒及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
KR20020034181A (ko) * 1999-08-27 2002-05-08 맥시겐 에이피에스 새로운 인터페론 베타-유사 분자
SK8292002A3 (en) * 1999-11-12 2002-12-03 Maxygen Holdings Ltd A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
HUP0500997A2 (en) * 2001-11-20 2007-11-28 Pharmacia Corp Chemically-modified human growth hormone conjugates
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
WO2003061577A2 (en) 2002-01-18 2003-07-31 Biogen Idec Ma Inc. Polyalkylene glycol with moiety for conjugating biologically active compound
US7345150B2 (en) 2002-03-26 2008-03-18 Medical University Of Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
ES2897470T3 (es) 2002-09-09 2022-03-01 Nektar Therapeutics Alcanales poliméricos solubles en agua
WO2005000360A2 (en) * 2003-05-23 2005-01-06 Nektar Therapeutics Al, Corporation Peg derivatives having an amidocarbonate linkage
US7405198B2 (en) * 2003-11-24 2008-07-29 Neose Technologies, Inc. Glycopegylated erythropoietin
KR20070042567A (ko) 2004-08-31 2007-04-23 파마시아 앤드 업존 캄파니 엘엘씨 글리세롤 분지쇄 폴리에틸렌 글리콜 인간 성장 호르몬공액체, 이의 제조 방법 및 이의 사용 방법
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
EP1869079A2 (en) * 2005-03-11 2007-12-26 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CN101002944B (zh) 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
CN101104078B (zh) 2006-07-11 2011-11-02 北京美倍他药物研究有限公司 多肽及蛋白药物的聚乙二醇偶合物
CN101108895B (zh) 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
CN1966547B (zh) 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
DK2196475T3 (da) 2007-09-04 2012-09-17 Biosteed Gene Expression Tech Co Ltd Interferon alfa 2a, som er modificeret med polyethylenglycol, fremgangsmåde til syntese deraf samt anvendelse deraf
PT2186830E (pt) 2007-09-04 2012-06-20 Biosteed Gene Expression Tech Co Ltd Interferão alfa 2b modificado com polietilenoglicol e método de preparação e aplicações do mesmo
CN101491682A (zh) 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN101671390B (zh) 2008-09-10 2012-10-03 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN101514229B (zh) 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物

Also Published As

Publication number Publication date
HUS2200039I1 (hu) 2022-09-28
EA201070282A1 (ru) 2010-08-30
DK2205281T3 (da) 2022-08-15
AU2008286742B2 (en) 2014-05-29
KR20100076945A (ko) 2010-07-06
CL2008002399A1 (es) 2009-01-02
EP4129343A1 (en) 2023-02-08
BRPI0814482A2 (pt) 2015-02-03
EP2205281B1 (en) 2022-06-29
NL301195I2 (nl) 2023-03-02
CN101367872A (zh) 2009-02-18
PT2205281T (pt) 2022-08-02
TW200916116A (en) 2009-04-16
AR067964A1 (es) 2009-10-28
FR22C1045I2 (fr) 2023-12-29
EP2205281A4 (en) 2014-10-08
UA103158C2 (ru) 2013-09-25
HRP20220937T3 (hr) 2022-09-30
ZA201001777B (en) 2010-12-29
JP5613050B2 (ja) 2014-10-22
NL301195I1 (el) 2022-08-31
LT2205281T (lt) 2022-09-26
AU2008286742A1 (en) 2009-02-19
WO2009023826A1 (en) 2009-02-19
US8143214B2 (en) 2012-03-27
NZ583831A (en) 2012-06-29
FR22C1045I1 (fr) 2022-10-14
CA2696478A1 (en) 2009-02-19
HUE059551T2 (hu) 2022-11-28
MX2010001750A (es) 2010-06-01
JP2010536788A (ja) 2010-12-02
EA018111B1 (ru) 2013-05-30
SI2205281T1 (sl) 2022-11-30
NO2022038I1 (no) 2022-09-02
CA2696478C (en) 2018-10-09
PL2205281T3 (pl) 2022-12-12
BRPI0814482B1 (pt) 2021-02-02
EP2205281A1 (en) 2010-07-14
US20090053177A1 (en) 2009-02-26
KR101588465B1 (ko) 2016-01-25
BRPI0814482B8 (pt) 2021-11-23
MY149148A (en) 2013-07-15
TWI381851B (zh) 2013-01-11
CN101367872B (zh) 2013-11-20
ES2924727T3 (es) 2022-10-10

Similar Documents

Publication Publication Date Title
CY1125751T1 (el) Συμπλοκα πρωτεϊνων-πολυμερων
CY1119988T1 (el) Αναστολεις του ιου της ηπατιτιδας c
CY1119896T1 (el) Μεθοδοι για αγωγη toy hcv
CY1123324T1 (el) Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων
CY1123152T1 (el) Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
CY1112999T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
CY1114298T1 (el) Διαμορφωτικως περιορισμενα διφαινυλ παραγωγα για χρηση ως αναστολεις ιου ηπατιτιδας c
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
EA201100390A1 (ru) Соединения для лечения гепатита с
CY1115253T1 (el) Κρυσταλλικες μορφες ενος παραγωγου 2-θειαζολυλο-4-κινολινυλ-οξυ-ομαδας, ενος ισχυρου αναστολεα του ηcv
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
EA200901490A1 (ru) Химические соединения
EA201301158A1 (ru) Противовирусные соединения
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
EA201591702A1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
CY1124220T1 (el) Θεραπεια της λοιμωξης του ιου της ηπατιτιδας δελτα με ιντερφερονη λαμδα
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
CY1116374T1 (el) Θεραπεια για τη λοιμωξη με τον ιο της ηπατιτιδας β μονο ή σε συνδυασμο με τον ιο της ηπατιτιδας δελτα και σχετιζομενες ασθενειες του ηπατος
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE525070T1 (de) Silbininkomponente zur behandlung von hepatitis
CY1117959T1 (el) 24-norudca για την αγωγη αυτοανοσης ηπατιτιδας
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич